The top 7 (US, EU4, UK, and Japan) necrotizing enterocolitis markets size are expected to exhibit a CAGR of 3.76% during 2025-2035.

The necrotizing enterocolitis (NEC) market is predicted to grow in 2025 due to greater awareness of the disease, improved preventative measures, and advances in monitoring and treatment technologies. Research-based innovation alongside improved clinical practices is helping tackle NEC, a life-threatening intestinal condition that affects primarily premature infants.

Rising Incidence and Market Impact

NEC is one of the most common gastrointestinal emergencies that occurs in the neonatal intensive care unit. The highest incidence is among infants born prior to 32 weeks; however, the improving survival rates of very preterm infants has noticeably increased the prevalence of NEC. While the increased survival rate is encouraging, it also broadens the risk population.

The rising incidence of NEC captures the attention of healthcare practitioners and creates a need for more specialized devices and systems. Enhanced human milk feeding strategies and donor milk programs are now more widely adopted. This trend, alongside hospitals’ aims to reduce NEC and improve overall outcomes for neonates, is increasing the demand for enhanced nutritional support and associated technologies.

Latest Market Trends

The market underwent a significant change in 2025 due to nutrition-based prevention. Clinical studies show that exclusive human milk feeding, especially when fortified with multi-nutrient supplements, reduces NEC risk. For this reason, neonatal units are purchasing more donor milk banks and human milk based fortifiers. It has become common practice to incorporate NEC prevention in neonatal care bundles, which combine feeding with infection control and gut health optimization. 

Another shift occurring in the market is the acceptance of microbial therapies. Probiotics for preterm infants are becoming more accepted due to the proven gut barrier integrity and inflammation reduction. This is part of a larger shift in preventative healthcare, where the focus is shifting from simply treating issues to encouraging long term health. 

Technological Advancements in 2025  

The last few years have seen a major shift in monitoring and early warning systems. Bedside tests for inflammation or intestinal damage are being developed to measure predictors of inflammation and NEC. These point-of-care tests aim to detect NEC long before any clinical symptoms worsen. In addition, ultrasound imaging on neonates has become automated and sensitive, allowing real-time monitoring of gut perfusion and wall thickening.

AI technology is becoming a part of NEC detection. AI algorithms assess vital signs, feeding tolerance, and preliminary blood work to notify clinicians of complex, early indicators suggesting NEC. These systems support proactive decisions and provide the care teams with necessary time for intervention. New wound healing and anti-inflammatory medicines are emerging in the treatment scope. Localized drug delivery systems like dosed intraluminal anti-inflammatory gels are advancing, with plans for initial human testing. These treatments strive to minimize surgical intervention by shielding the intestinal lining.  

Looking Ahead  

The necrotizing enterocolitis market is expected to shift focus by 2025 from NEC treatment to prevention with early and proactive intervention. Advanced nutrition, microbial therapy, real-time tracking systems, and early-stage pharmacotherapy converge toward a comprehensive care model. NEC will continue to be a challenging concern as the survival rate of preterm infants rises, but the market is aggressively progressing to improving preventive methods, swift diagnosis, and streamlined treatment. This shift will strengthen outcomes for infants in critical condition. Patients will benefit from a holistic approach in their integrated and individualized plan during neonatal care.

Request for a sample of this report: https://www.imarcgroup.com/necrotizing-enterocolitis-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country: 

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the necrotizing enterocolitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the necrotizing enterocolitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current necrotizing enterocolitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the necrotizing enterocolitis market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Infant Bacterial Therapeutics

2. Leadiant Biosciences

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=10232&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145